Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.
After an unsuccessful commercialization attempt more than a decade ago, the company is bringing a revamped version of the ion mobility technology to market.
The BD business, which has annual revenues of about $100 million, offers technical services as well as peptones for cell culture media used in biopharmaceutical applications.
The method combines stable isotope dimethyl labeling with DiLeu isobaric tagging and allows multiplexing of up to 24 samples in a single mass spec experiment.
NYSDOH's move away from susceptibility testing for isolates that are known to be pan-susceptible will be coordinated with similar international efforts.
The move is precipitated by CMS's decision to grant national coverage to NGS companion diagnostics when they're approved by the FDA.
The lawsuit makes broad accusations that companies stole trade secrets related to universal array technology.
The company's revenues totaled $6.08 billion, up from $4.99 billion during Q2 of 2017.
The study, which coupled FAIMS to an Orbitrap mass spec, indicates the technology could streamline proteomics experiments without sacrificing depth of analysis.
In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."
Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.
Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.
In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.